Prof Nicoletta Colombo speaks to ecancer.tv about trabectedin, a drug that has recently been approved for use with pegylated liposomal doxorubicin to treat partially platinum sensitive recurrent ovarian cancer patients. This treatment successfully increases the platinum free interval in partially platinum sensitive patients, thereby increasing treatment efficacy. Prof Colombo discusses a further trial planned to determine if the extension in platinum free interval is translated into an improvement in overall survival.